Vaxxinity, Inc. (VAXX)

Market Cap	98.30M
Revenue (ttm)	n/a
Net Income (ttm)	-66.00M
Shares Out	112.87M
EPS (ttm)	-0.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	542,493
Open	0.890
Previous Close	0.848
Day's Range	0.820 - 0.890
52-Week Range	0.800 - 4.470
Beta	3.14
Analysts	Buy
Price Target	7.00 (+703.77%)
Earnings Date	Nov 8, 2023

About VAXX

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2021
• Employees: 87
• Stock Exchange: NASDAQ
• Ticker Symbol: VAXX

Analyst Forecast

According to one analyst, the rating for VAXX stock is "Buy" and the 12-month stock price forecast is $7.0.

Price Target

$7.0

(703.77% upside)

Analyst Consensus: Buy